cardiorenal medicine
MannKind to Acquire scPharmaceuticals in Up to $360M Deal
MannKind; scPharmaceuticals; acquisition; Furoscix; cardiorenal medicine; cardiometabolic diseases; FDA-approved infuser; ReadyFlow autoinjector; merger agreement; tender offer